Stockscreener 앱 받기
1.28
36.46%
0.342
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Xilio Therapeutics Enters into Additional Private Placement with Gilead; Issues Securities at $25 Million Aggregate Investment - Defense World
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com - Investing.com Canada
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock - Investing.com India
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian
Xilio Therapeutics to Present Initial Phase 2 Data for - GlobeNewswire
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - Yahoo Finance
Xilio Therapeutics Hires Caroline Hensley as Chief Legal Officer - Bloomberg Law
Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - The Bakersfield Californian
Xilio Therapeutics, Inc. Appoints Caroline Hensley as chief legal officer - Marketscreener.com
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - MSN
Here's Why We're Not Too Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Yahoo Finance
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00 - Defense World
Xilio Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Xilio Therapeutics Inc. (XLO) Quarterly 10-Q Report - Quartzy
Xilio to present new cancer treatment data at SITC - Investing.com
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - citybiz
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors - GlobeNewswire
Xilio's Cancer Drug Shows Promise: Liver Metastasis Resolution in Clinical Trial | XLO Stock News - StockTitan
Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.
Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St
Xilio Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of - The Bakersfield Californian
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan
XOS stock touches 52-week low at $4.62 amid market challenges - Investing.com
XBP stock plunges to 52-week low at $1.05 amid market challenges - Investing.com
XPEV: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Xilio Therapeutics Inc (XLO) rating initates by Chardan Capital Markets - Knox Daily
Market Resilience: XTI Aerospace Inc. (XTIA) Finishes Weak at 0.22, Down -4.06 - The Dwinnex
Tencent-Backed AI Drug Researcher Xtalpi’s Shares Double On Revenue Rise - Forbes Africa
Xilio Therapeutics Inc (XLO)’s highs and lows: A closer look at its stock price fluctuations - US Post News
(XFLT) Trading Signals - Stock Traders Daily
Balance Sheet Breakdown: Xilio Therapeutics Inc (XLO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
There’s evidence fragile X symptoms can be reduced with an experimental drug - KUOW News and Information
Slew of New Drugs Sends Xencor Shares Soaring - Los Angeles Business Journal
XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.63 - Defense World
XTX Topco Ltd Has $2.01 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV) - Defense World
Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com India
Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
XLO Stock Sees Decline of Approximately -10.26% in Last Five Days - Knox Daily
Analytical Lens: Exploring Xilio Therapeutics Inc (XLO)’s Financial Story Through Ratios - The Dwinnex
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewswire
Xilio Therapeutics shares hold Buy rating on clinical trial focus - Investing.com
Xilio Therapeutics shares hold Buy rating on clinical trial focus By Investing.com - Investing.com Canada
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results - GlobeNewswire
2.88%
2.65%
자본화:
|
볼륨(24시간):